Staffing and Funding. 1. All identification, evaluation, and treatment efforts shall be conducted under the supervision of personnel who meet applicable professional qualifications.
Staffing and Funding. ACE has provided staffing and funds sufficient to develop and implement appropriate compliance measures throughout the United States.
Staffing and Funding. Lilly shall provide research funds (the "Research Funds") for the Research Program and Development Program and Ligand shall during each Research Year assign to the Research Program and Development Program sufficient personnel to provide no less than the number of Scientific Person Years reflected in the schedule below. At least *** of the Scientific Person Years shall be provided by scientists with a Ph.D. or M.D. degree or *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. equivalent academic credentials. Ligand shall, from time to time, consult with Lilly regarding assignment of Ligand personnel to the Research Program and Development Program and shall consider in good faith any changes suggested by Lilly. Ligand shall not, to the disadvantage of the Research Program and Development Program, transfer personnel from the professional staff engaged in the Research Program and Development Program to participate in another program. The amount of Research Funds to be paid by Lilly shall be *** per Scientific Person Year *** . Commencing January 1, 1999 and on January 1 of each year thereafter, the amount to be paid by Lilly per Scientific Person Year will be increased by *** over the amount applicable to the immediately preceding Calendar Year. The following table shows the allocation of research scientists presently contemplated by the parties. The resources shown in the table for Targretin will support the further development of Targretin as contemplated by the Targretin Agreement. The Steering Committee, from time to time, may reallocate such resources as it deems appropriate. RESEARCH YEAR 1 2 3 4 5 *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** Total *** *** *** *** ***
Staffing and Funding. Lilly shall pay to Ligand such research funds with respect to Drug Product, as are provided in the Collaboration Agreement. Lilly shall pay Ligand for costs incurred by Ligand in association with the performance of the preclinical activities required for the development of the Drug Products, as provided in Section 3.3. The resource requirements for the Research Program and the Development Program shall be determined by the Joint Program Committee and approved by the Alliance Directors Committee. Each party shall provide with respect to the Research Program and the Development Program such accounting, research and other information as is required of such party pursuant to the Collaboration Agreement. For reimbursement by Lilly to Ligand of costs associated with the Research Program and the Development Program, Lilly shall have such audit and review rights as are provided in the Collaboration Agreement. Staffing levels and credentials for personnel provided by Ligand shall be as set forth in the Collaboration Agreement.
Staffing and Funding. Subject to the fulfillment of all terms and conditions of this Agreement, Lilly shall provide research funds (the "Research Funds") as described in this Section for the Research Program during the Research Term and Vertex shall during each Research Year assign to the Research Program sufficient personnel to provide no less than [*]. Vertex intends to dedicate to this Program scientists who have an optimal combination of experience and training in the Field. During the Research Term, Lilly shall fund the Research Program as follows: Upon signature of this Agreement $3.00 Million Research Year 1 [*] Research Year 2 [*] Research Year 3 [*] Research Year 4 [*] Research Year 5 [*] Research Year 6 [*]
Staffing and Funding
